Glen C. MacDonald - Feb 18, 2022 Form 4 Insider Report for Sesen Bio, Inc. (CARM)

Role: Chief Technology Officer
Signature: /s/ Mark R. Sullivan, attorney-in-fact
Stock symbol: CARM
Transactions as of: Feb 18, 2022
Transactions value $: $0
Form type: 4
Date filed: 2/23/2022, 07:33 PM
Next filing: Feb 23, 2023

Transactions Table

Type	Sym	Class	Transaction	Value $	Shares	Change %	* Price $	Shares After	Date	Ownership	Footnotes
transaction	CARM	Common Stock	Award	$0	+309K		$0.00	309K	Feb 18, 2022	Direct	F1

* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id	Content
F1	Represents restricted stock units ("RSUs") which shall vest annually in equal amounts over a four-year period following the grant date, so long as the reporting person remains employed by Sesen Bio, Inc. (the "Company"). Each RSU represents a contingent right to receive one share of the Company's common stock. The compensation committee of the Company approved the grant to the reporting person, based on market analysis by Radford of public, pre-commercial and commercial biopharmaceutical companies.

Content

Represents restricted stock units ("RSUs") which shall vest annually in equal amounts over a four-year period following the grant date, so long as the reporting person remains employed by Sesen Bio, Inc. (the "Company"). Each RSU represents a contingent right to receive one share of the Company's common stock. The compensation committee of the Company approved the grant to the reporting person, based on market analysis by Radford of public, pre-commercial and commercial biopharmaceutical companies.